News

More efzofitimod exposure linked to better lung function in trial

Greater exposure to the experimental treatment efzofitimod led to a more pronounced improvement in lung function for people with pulmonary sarcoidosis in a Phase 1/2 clinical trial, according to a new analysis. Scientists at aTyr Pharma, the company developing the first-in-class immunomodulatory therapy, presented their findings at…

Only 1 in 6 people get definite neurosarcoidosis diagnosis: Study

Despite advances in testing, fewer than one of every six people evaluated for suspected neurosarcoidosis — sarcoidosis affecting the nervous system — received a definite diagnosis of the inflammatory disorder, according to a 30-year study in Sweden. A confirmed neurosarcoidosis diagnosis in those cases was made only following a…

AAN 2023: Muscle symptoms not always caused by granulomas

Only about half of sarcoidosis patients showing signs of muscle disease, or myopathy, have the small clumps of immune cells in their muscles that characterize sarcoidosis, a study showed. When these clumps, called granulomas, weren’t present with muscle symptoms, myopathy was most often linked to inclusion body myositis (IBM),…

Sarcoidosis-associated lung bleeding may be more common than known

A lung bleeding condition called diffuse alveolar hemorrhage (DAH) may develop secondary to sarcoidosis more frequently than previously reported, a small study suggests. Considering the frequency of DAH associated with sarcoidosis reported in the study, “it is essential to consider sarcoidosis in the differential diagnosis of immune-mediated DAH,” the researchers…